Researchers have kicked off a patient recruitment drive as they explore the safety and efficacy of cannabis oil for the treatment of musculoskeletal chronic pain.
The observational study, sponsored by Levin Health, is looking for 100 people who have received no respite from conventional treatment.
The primary endpoint will examine pain scores while secondary measures will evaluate the effects of the cannabis medication on depression, anxiety, sleep quality, stress and quality of life.
The study will see participants administered one of three oil medications over 12 weeks or until they cease the medication.
The principal investigator is WA-based prescriber, Dr Matty Moore, with Sharlene Mavor the associate investigator and study co-ordinator.
The study will require participants to complete a baseline and then weekly standardised and validated patient reported outcome measure (PROM) questionnaire in which they will note any improvement.
Participants must be over 18 years of age and have diagnosed treatment-resistant chronic pain of musculoskeletal origin.
The eligibility questionnaire can be found here.
Source: Cannabiz Licensed by Copyright Agency. You must not copy this work without permission.Designed to help you stay informed about the latest developments in the Australian medicinal cannabis landscape, this page includes curated articles covering key legislative changes, scientific research, and industry trends.